<DOC>
	<DOCNO>NCT00618293</DOCNO>
	<brief_summary>Evaluation efficacy determination transfusion requirement safety determination adverse event administration Von Willebrand factor concentrate F VIII ( Haemate ) .</brief_summary>
	<brief_title>Haemate HS Patients With Severe Bleeding Undergoing Valve Replacement Due Aortic Stenosis</brief_title>
	<detailed_description />
	<mesh_term>Constriction , Pathologic</mesh_term>
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Aortic Valve Stenosis</mesh_term>
	<mesh_term>Blood Loss , Surgical</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<criteria>patient isolate valvular aortic stenosis combine aorticvalve defect prevail stenosis severe bleed aorticvalve replacement Caucasian write informed consent ( Classification bleed `` normal '' , `` moderate '' `` excessive '' surgeon.Classification excessive lead recruitment ) active endocarditis history suggestive inherit oe acquire bleed disorder concomitant coronary heart disease agent impair platelet function 14 day surgery Pregnancy inherit platelet function know intolerance HAEMATE HS previous thromboembolic complication Hepatitis B , C HIV infection previous chemotherapy emergency surgery within last 7 day weight &lt; 50 kg &gt; 100 kg</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>intraoperative bleeding</keyword>
	<keyword>aortic-valve replacement</keyword>
	<keyword>aortic stenosis</keyword>
	<keyword>Von Willebrand</keyword>
	<keyword>HEAMATE</keyword>
</DOC>